CD8A and neoplasm: The same treatment group had a larger proportion of CD4+ T and CD8+ memory/effector T cells (CD3+CD4+CD44+ and CD3+CD8+CD44+, respectively) among tumor-infiltrating leukocytes, suggesting that the anti–MMP-9/anti-PDL1 combination promotes a functional T cell–mediated antitumor response.